


RESEARCH ARTICLE

Cyclobenzaprine Raises ROS Levels in *Leishmania infantum* and Reduces Parasite Burden in Infected Mice

Edézio Ferreira Cunha-Júnior¹, Valter Viana Andrade-Neto¹, Marta Lopes Lima^{2,3}, Thais Alves da Costa-Silva³, Andres J. Galisteo Junior², Maria A. Abengózar⁴, Coral Barbas⁵, Luis Rivas⁴, Elmo Eduardo Almeida-Amaral¹, Andre Gustavo Tempone³, Eduardo Caio Torres-Santos^{1*}

1 Laboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brasil, **2** Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, São Paulo, Brazil, **3** Centro de Parasitologia e Micologia, Instituto Adolfo Lutz, São Paulo, São Paulo, Brazil, **4** Centro de Investigaciones Biológicas (CSIC), Unidad Asociada Interacciones, Metabolismo y Bioanálisis CSIC-CEU, Madrid, Spain, **5** Center for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad CEU San Pablo, Madrid, Spain

* ects@ioc.fiocruz.br


 OPEN ACCESS

Citation: Cunha-Júnior EF, Andrade-Neto VV, Lima ML, da Costa-Silva TA, Galisteo AJ Junior, Abengózar MA, et al. (2017) Cyclobenzaprine Raises ROS Levels in *Leishmania infantum* and Reduces Parasite Burden in Infected Mice. *PLoS Negl Trop Dis* 11(1): e0005281. doi:10.1371/journal.pntd.0005281

Editor: Michael P Pollastri, Northeastern University, UNITED STATES

Received: July 5, 2016

Accepted: December 21, 2016

Published: January 3, 2017

Copyright: © 2017 Cunha-Júnior et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by Programa Estratégico de Apoio à Pesquisa em Saúde, FIOCRUZ/Conselho Nacional de Desenvolvimento Científico e Tecnológico - www.cnpq.br, (PAPES/CNPq 407680/2012-8 to ECTS and 407590/2012-9 to EEA), Fundação de Apoio a Pesquisa do Estado do Rio de Janeiro - www.faperj.br (Fellow and grant E-26/010.001828/2016 to EFCJ), Conselho

Abstract

Background

The leishmanicidal action of tricyclic antidepressants has been studied and evidences have pointed that their action is linked to inhibition of trypanothione reductase, a key enzyme in the redox metabolism of pathogenic trypanosomes. Cyclobenzaprine (CBP) is a tricyclic structurally related to the antidepressant amitriptyline, differing only by the presence of a double bond in the central ring. This paper describes the effect of CBP in experimental visceral leishmaniasis, its inhibitory effect in trypanothione reductase and the potential immunomodulatory activity.

Methodology/Principal Findings

In vitro antileishmanial activity was determined in promastigotes and in *L. infantum*-infected macrophages. For *in vivo* studies, *L. infantum*-infected BALB/c mice were treated with CBP by oral gavage for five days and the parasite load was estimated. Trypanothione reductase activity was assessed in the soluble fraction of promastigotes of *L. infantum*. For evaluation of cytokines, *L. infantum*-infected macrophages were co-cultured with BALB/c splenocytes and treated with CBP for 48 h. The supernatant was analyzed for IL-6, IL-10, MCP-1, IFN- γ and TNF- α . CBP demonstrated an IC₅₀ of 14.5 \pm 1.1 μ M and an IC₉₀ of 74.5 \pm 1.2 μ M in promastigotes and an IC₅₀ of 12.6 \pm 1.05 μ M and an IC₉₀ of 28.7 \pm 1.3 μ M in intracellular amastigotes. CBP also reduced the parasite load in *L. infantum*-infected mice by 40.4 \pm 10.3% and 66.7 \pm 10.5% in spleen at 24.64 and 49.28 mg/kg, respectively and by 85.6 \pm 5.0 and 89.3 \pm 4.8% in liver at 24.64 and 49.28mg/kg, after a short-term treatment. CBP inhibited the trypanothione reductase activity with a Ki of 86 \pm 7.7 μ M and increased the ROS production in

Nacional de Desenvolvimento Científico e Tecnológico (CNPq/Universal grant 470627/2013-1 to EEAA), São Paulo Research Foundation - www.fapesp.br (FAPESP 2015/23403-9 to AGT), Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad FEDER - www.idi.mineco.gob.es/ (SAF2015-65740-R) and Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER - www.isciii.es/ (RD12/0018/0007) (to LR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

promastigotes. CBP inhibited in 53% the production of IL-6 in infected macrophages co-culture.

Conclusion/Significance

To the best of our knowledge, this study is the first report of the *in vivo* antileishmanial activity of the FDA-approved drug CBP. Modulation of immune response and induction of oxidative stress in parasite seem to contribute to this efficacy.

Author Summary

Leishmaniasis is the denomination of a worldwide widespread group of tropical neglected diseases caused by protozoa belonging to *Leishmania* genus. Several factors have competed to worsen its spreading, such as climate changes and the recent conflict in Syria. The visceral form is the most severe among them and it is fatal if untreated. There is no vaccine for humans and the therapeutic arsenal is quite limited. Drug repurposing is a strategy that aims to look for new uses for well established drugs. This approach has been pointed as an attractive option to fasten the development of new treatment for leishmaniasis. Here, the authors evaluated the activity of cyclobenzaprine (CBP), a classical muscle relaxant, in a murine model of visceral leishmaniasis and investigated mechanisms involved in its leishmanicidal action. CBP was effective in reducing the parasite burden both in cell culture and in the liver and spleen of *Leishmania*-infected mice. Furthermore, the experimental data suggested that CBP interferes in the redox balance of the parasite and modulates the immune response of the host. Altogether, these results encourage further studies to evaluate the therapeutic usage of cyclobenzaprine for leishmaniasis.

Introduction

The research and development of new drugs is a slow and costly process. In addition to the different clinical forms caused by over 20 species of *Leishmania*, the drug resistance increases the complexity of the challenge [1]. Drug repurposing is an interesting strategy to speed up and reduce costs in Drug Discovery and Development [2]. Since the 1980s, the antileishmanial action of tricyclic drugs has been studied [3] and there are evidences that their action is linked to inhibition of trypanothione reductase [4], a key enzyme in the redox metabolism of pathogenic trypanosomes [5]. Cyclobenzaprine is a skeletal muscle relaxant, structurally related to the tricyclic compound amitriptyline, differing only by the presence of a double bond in the central ring. Within this context, we demonstrated the effect of cyclobenzaprine in experimental visceral leishmaniasis, and studied the potential inhibitory effect in trypanothione reductase and also the immunomodulatory activity.

Materials and Methods

Ethics statement

This study was performed in accordance with the guidelines of the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (COBEA) and had the approval of the Animal Ethics Committee of Oswaldo Cruz Foundation (license number L-026/2015).

Parasites

The *Leishmania infantum* (MHOM/MA/67/ITMAP-263) used in this study is a well-established strain and was kindly provided by Instituto de Biologia Molecular e Celular, Porto University, Portugal.

Chemicals

Cyclobenzaprine (CBP), DTNB (Ellman's reagent), propidium iodide (PI), resazurin, lipopolysaccharide (LPS), concanavalin A (ConA), miltefosine and rhodamine 123 were purchased from Sigma-Aldrich (St Louis, USA), 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA) from Molecular Probes (Eugene, USA), and Glucantime from Sanofi-Aventis (São Paulo, Brazil).

In vitro antileishmanial assays

Promastigotes of *L. infantum* (strain MHOM/MA/67/ITMAP-263) at 1.0x10⁶ cells/mL were cultivated with cyclobenzaprine in triplicate (0–50 μM) at 26°C in Schneider's medium (Sigma-Aldrich) supplemented with 20% heat-inactivated fetal calf serum (HIFCS), for 72 h. Inhibition of parasite growth was assessed employing resazurin [6].

For the intracellular amastigote assay, resident peritoneal macrophages were collected from BALB/c mice, plated in RPMI (Sigma-Aldrich) at 2x10⁶ cells/mL in duplicate, infected with promastigotes of *L. infantum* (5:1) and incubated at 37°C in 5% CO₂ for 4 h. After washing, macrophages were incubated with cyclobenzaprine for further 72 h. The slides were stained and the amastigotes were counted using light microscopy.

Experimental visceral leishmaniasis

Dose Translation: The initial dose was calculated based on the human dose, as follows [7]: Animal dose (mg/kg) = (human K_m / animal K_m) x human dose (mg/kg), where mouse K_m = 3, human K_m = 37.

Protocol: BALB/c mice (five per group) were infected intraperitoneally with 1.0x10⁸ stationary-phase *L. infantum* promastigotes [8–10]. After 25 days, mice were treated with three CBP doses (12.32, 24.64 and 49.28 mg/kg) by oral gavage for five days [11]. Control groups were treated with miltefosine 20.55 mg/kg and vehicle (water). After the treatment, the animals were euthanized and spleen and liver were aseptically removed and the parasite load was estimated by limiting dilution assay (LDA) [12]. The serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured using laboratory colorimetric diagnostic kits (Dolex, Goiânia, Brazil).

Trypanothione reductase activity

The assay was adapted from Hamilton *et al.* [13]. Briefly, promastigotes of *L. infantum* were centrifuged and resuspended in buffer containing 40 mM HEPES, 1 mM EDTA and protease inhibitor cocktail (Sigma-Aldrich). The parasites were lysed and centrifuged at 17,500g/15 min. The supernatant was considered to contain the trypanothione reductase (TryR). The assay was performed in triplicate with: 40 mM HEPES (pH 7.5), 1 mM EDTA, 100 μM of DTNB (Ellman's reagent), 1 μM substrate (trypanothione trifluoroacetate, Sigma-Aldrich), 0.1 mM NADPH and different concentrations of cyclobenzaprine (0–100 μM). Reading was initiated after adding 4 mg/mL soluble protein (enzyme) at 410nm using a Spectra Max M2 spectrofluorometer (Molecular Devices, Silicon Valley, CA, USA) at 10 min intervals for 1 h. Clomipramine was used as positive control (PC). This drug has well-known action on the

inhibition of trypanothione reductase enzyme [14]. Apparent K_i was assumed to be the value of the 50% inhibitory concentration obtained from the dose-response curve inhibition of TryR by CBP in 60 minutes. K_i value was determined by nonlinear least-squares fitting of these data to the 4-parameter logistic plot equation, as described by Holloway GA, Charman WN, Fair-lamb AH, *et al.*, (2009): $y = A + \{(B - A) / [1 + (C/x)^D]\}$ [15].

Measurement of ROS

Intracellular ROS levels were measured as described by Ribeiro *et al* [16]. Briefly, 1×10^7 promastigotes/mL of *L. infantum* were incubated with CBP (0 to 50 μM) in the presence of 20 μM H_2DCFDA in Schneider's medium with 20% HIFCS. The fluorescence was quantified at 1 h intervals for 6 h.

Evaluation of cytokines and nitric oxide production

Briefly, macrophages obtained from peritoneal cavity were plated at 1×10^5 cells/mL in a 24 well plate with complete RPMI 1640 medium supplemented with 10% HIFCS and infected overnight with amastigotes of *L. infantum* (ratio 10:1). After 18 hours of infection, macrophages were co-cultured with splenocytes obtained from BALB/c mouse at a ratio 1:6. Cells were treated with a non-toxic concentration of CBP (100 μM) for 48 h. Afterwards, the cell supernatant was analyzed for IL-6, IL-10, monocyte chemoattractant protein-1 chemokine (MCP-1), IFN- γ and TNF- α levels using flow cytometry and the Cytometric Beads Array (CBA) kit (BD Bioscience, San Diego, CA, USA). Controls consisted of sham-treated macrophages infected with *L. infantum*, LPS (1 $\mu\text{g}/\text{mL}$) and concanavalin A (1 $\mu\text{g}/\text{mL}$), and the negative control (macrophages without the drug). The nitric oxide content was colorimetrically determined by the Griess reaction in the culture supernatants of peritoneal macrophages [17]. Cells were treated for 24 h with cyclobenzaprine at 12 μM , corresponding to the IC_{50} value against intracellular amastigotes. Bacterial lipopolysaccharide (LPS) was used as positive control (1 $\mu\text{g}/\text{mL}$). The obtained results were extrapolated from a standard curve prepared with NaNO_2 at different concentrations (0 to 400 μM).

Statistical analysis. Results are represented as the mean and standard deviation of replicates samples from at least two independent assays. IC_{50} values were calculated using sigmoidal dose-response curves using GraphPad Prism 5.0 software. Test T was used for significance testing ($p < 0.05$).

Results

In vitro activity

CBP demonstrated a concentration-dependent activity in *L. infantum* promastigotes growth, with an IC_{50} value of $14.5 \pm 1.1 \mu\text{M}$ and an IC_{90} value of $74.5 \pm 1.2 \mu\text{M}$ (Fig 1A). The drug was also effective against clinically relevant forms, the intracellular amastigotes, with an IC_{50} of $12.6 \pm 1.05 \mu\text{M}$ and an IC_{90} of $28.7 \pm 1.3 \mu\text{M}$ (Fig 1B). The treatment with 50 μM reduced this index by 99% when compared to control (insert Fig 1B).

Experimental visceral leishmaniasis

Cyclobenzaprine was effective in reducing the parasite load by $40.4 \pm 10.3\%$ and $66.7 \pm 10.5\%$ in spleen at 24.64 and 49.28 mg/kg, respectively (Fig 2A) and by 85.6 ± 5.0 and $89.3 \pm 4.8\%$ in liver at 24.64 and 49.28 mg/kg (Fig 2B), after a short-term treatment. We did not observe changes in hepatic transaminases levels in groups treated with CBP. However, there was a significant increase of ALT level in the group treated with 20.55 mg/kg of miltefosine.




Fig 1. In vitro activity of CBP. (A) Promastigotes of *L. infantum* were incubated with CBP for 72 h. The growth inhibition was measured using resazurin. (n = 3) (B) Peritoneal macrophages were infected with *L. infantum* and treated with CBP for 72 h. The slides were stained and the results were expressed as an infection index[#] [Ii = % infected cells × (number of amastigotes/total number of macrophages)]. The inset shows representative photos from the slides. (n = 3).

doi:10.1371/journal.pntd.0005281.g001




Fig 2. In vivo activity of CBP. *L. infantum*-infected BALB/c mice were treated after 25 days of infection for 5 consecutive days, with CBP 12.32, 24.64 and 49.28mg/kg, by oral route. Control groups were treated with miltefosine 20.55mg/kg (reference drug—M20.55) and vehicle (water). The parasite load was estimated using a parasite-limiting dilution assay (LDA) in spleen (A) and liver (B). The serum levels of aspartate aminotransferase (AST) (C) and alanine aminotransferase (ALT) (D) after five days of treatment were measured using laboratory colorimetric diagnostic kits (n = 5) *p<0.05; **p<0.01.

doi:10.1371/journal.pntd.0005281.g002




Fig 3. Effect of CBP on TryR and ROS production. (a) *TryR* assay. Soluble extract of promastigotes of *L. infantum* using oxidized trypanothione as substrate and clomipramine (50 μ M) as positive control (PC) of inhibition. Reading was initiated after adding 100 μ M of DTNB at 410nm (n = 3). (b) *ROS* production. Promastigotes of *L. infantum* were incubated with CBP and ROS generation was measured with H₂DCFDA reagent. Antimycin A 10 μ M was used as positive control (PC). (n = 3) *p<0.05, ** p<0.01 and ***p<0.001.

doi:10.1371/journal.pntd.0005281.g003

Biochemical alterations of cyclobenzaprine on *L. infantum*

CBP inhibited the TryR activity in a concentration-dependent manner (Fig 3A), with a K_i of $86 \pm 7.7 \mu$ M. CPB also increased the ROS production in promastigotes in a time and concentration-dependent manner in the first 6 hours, consistent with TryR inhibition (Fig 3B).

Immunomodulatory activity

Flow cytometry data demonstrated that CBP inhibited the production of IL-6 in infected macrophages, decreasing the production of this cytokine by 53% when compared to untreated

macrophages (Fig 4a and 4b). MCP-1 levels of macrophages co-cultured with splenocytes were not altered by CBP treatment (Fig 4c and 4d). The control of cytokines production was confirmed in the LPS and ConA-treated groups. The treatment of macrophages with CBP resulted in unaltered levels of TNF- α , IFN- γ and IL-10 (Fig 4e–4j). Griess assay demonstrated an upregulation of nitric oxide levels of 3.2 times in macrophages incubated with CBP (Fig 5).

Discussion

Tricyclic antidepressants have shown potential against different *Leishmania* species with effectiveness based on the three ring structure and potency relying on specific molecular substitutions. Amitriptyline, which lacks the nitrogen in the central ring, is 10-fold more active against promastigotes of *L. donovani* than its nitrogen-substituted derivative, imipramine [18]. In this work we demonstrated for the first time in literature the in vitro and in vivo antileishmanial potential of cyclobenzaprine, a tricyclic derivative structurally related to amitriptyline. Our data demonstrated that CPB was effective against the intracellular amastigotes of *L. infantum*, with a IC₅₀ value close to that reported for amitriptyline for *L. donovani* and *L. amazonensis* intracellular amastigotes [19].

Trypanothione reductase is an essential component of the antioxidant defenses of trypanosomatids [5]. Interestingly, some tricyclic antidepressants have been reported to inhibit the TryR, as clomipramine, which showed a potent effect with a Ki of 6.53 μ M on recombinant TR from *Trypanosoma cruzi* [14]. Here, we demonstrated that CBP also inhibited *L. infantum* TryR activity at similar Ki value to those reported for amitriptyline [14], but with a reduced affinity when compared to clomipramine. Furthermore, it was also observed that promastigotes treated with CBP increased the intracellular concentration of ROS, in the same concentration range for TryR inhibition. Nevertheless, the concentration of CBP required to inhibit TryR and to induce ROS accumulation in the first hours of incubation was higher to that required to eliminate the parasites after 72 h. These data suggest a cumulative effect of inhibition of TryR at lower concentrations of CBP in 72 h or concomitant off-target effects of CBP contributing to the parasite death.

Immunomodulatory activity of drugs has also been implicated in the parasite control. In addition to the effective antileishmanial activity observed for CBP, its immunomodulatory potential was evaluated. Considered as a positive effect for *Leishmania* control, our data demonstrated that CPB induced a decrease of IL-6 levels in *Leishmania*-infected macrophages. Cytokines such as IL-6 and IL-10 play a critical role in regulating macrophage activation. Several clinical and experimental studies show that both IL-6 and IL-10 are involved in pathogenesis of VL; elevated levels of IL-6 has been associated to a preceding death event in VL patients [20]. It has also been reported that patients with active VL have higher serum levels of IL-10 and IL-6, evidencing their association with disease persistence [21]. Other studies with phenylpropanoid derivatives, demonstrated a correlation between the downregulation of IL-6 and IL-10 with the control of the infection in the *Leishmania*-infected macrophages [22]. Jek and co-workers [23] demonstrated that blocking NO production in rat macrophages results in an increased IL-1 and IL-6 secretion. Our assays demonstrated an upregulation of NO levels in macrophages incubated with CBP. The potential anti-inflammatory effect of nitric oxide has been described in human alveolar macrophages, followed by a downregulation of proinflammatory cytokines, including IL-6 [24, 25]. Based in these data, we could hypothesize that the antileishmanial effect of CBP involves an immunomodulatory effect in macrophages, increasing NO levels which consequently reduces an exacerbatory cytokine (IL-6) in leishmaniasis.




Fig 4. In vitro immunomodulation of CBP. *Leishmania*-infected (B, D, F, H and J) and uninfected macrophages (A, C, E, G and I), co-cultured or not with splenocytes and treated with 100 μ M of CBP; MØ (macrophages), Spl (splenocytes); LPS (lipopolysaccharide); ConA (concanavalin A). Cytokine levels were measured by CBA (cytometric beads array—BD Biosciences) in supernatant of cells after 48 h. Spl were not infected with *Leishmania*. (A and B) IL-6, (C and D) MCP-1, (E and F) TNF- α , (G and H) INF- γ and (I and J) IL-10. Cytokine levels were expressed as a significant experiment of two independent assays (n = 2). *p<0.05.

doi:10.1371/journal.pntd.0005281.g004




Fig 5. Increase of Nitric Oxide levels in macrophages treated with CBP. The production of nitric oxide (NO) by macrophages was measured after 24 h incubation with cyclobenzaprine (12 µM). The nitric oxide content was colorimetrically determined by the Griess reaction in the culture supernatants. Lipopolysaccharide (LPS) was used as positive control (1 µg/mL) (C). (n = 3) *p<0.05.

doi:10.1371/journal.pntd.0005281.g005

Conclusion

To the best of our knowledge, this study is the first report of the *in vitro* and *in vivo* antileishmanial activity of the FDA-approved drug CBP. Modulation of macrophage immune response and induction of oxidative stress in parasite seem to contribute to this efficacy, but additional effects may be further investigated. Altogether, these findings point out CBP as a candidate for further studies against visceral leishmaniasis.

Author Contributions

Conceptualization: EFCJ VVAN CB LR EEAA AGT ECTS.

Formal analysis: EFCJ MLL AGT ECTS.

Investigation: EFCJ VVAN MLL TAdCS AJGJ MAA.

Visualization: EFCJ AGT ECTS.

Writing – original draft: EFCJ VVAN MLL CB LR EEAA AGT ECTS.

Writing – review & editing: EFCJ MLL LR EEAA AGT ECTS.

References

1. WHO technical report series. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. [Internet]. World Health Organization technical report series.
2. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. *Nat Rev Drug Discov.* 2004; 3: 673–683. doi: [10.1038/nrd1468](https://doi.org/10.1038/nrd1468) PMID: [15286734](https://pubmed.ncbi.nlm.nih.gov/15286734/)

3. Zilberstein D, Dwyer DM. Antidepressants cause lethal disruption of membrane function in the human protozoan parasite *Leishmania*. *Science*. 1984; 226: 977–9. PMID: [6505677](#)
4. Kumar S, Ali MR, Bawa S. Mini review on tricyclic compounds as an inhibitor of trypanothione reductase. *J Pharm Bioallied Sci*. 2014; 6: 222–228. doi: [10.4103/0975-7406.142943](#) PMID: [25400403](#)
5. Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A. Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. *Science*. 1985; 227: 1485–1487. PMID: [3883489](#)
6. Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, et al. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of *Leishmania donovani*. *Parasitol Res*. 2013; 112: 825–828. doi: [10.1007/s00436-012-3212-3](#) PMID: [23239091](#)
7. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *FASEB J*. 2008; 22: 659–61. doi: [10.1096/fj.07-9574LSF](#) PMID: [17942826](#)
8. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. *Antimicrob Agents Chemother*. 1992; 36: 1630–1634. PMID: [1329624](#)
9. Rolão N, Melo C, Campino L. Influence of the inoculation route in BALB/c mice infected by *Leishmania infantum*. *Acta Trop*. 2004; 90: 123–126. PMID: [14739031](#)
10. Rodrigues R. The in vivo activity of 1, 3, 4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis. *J Antimicrob Chemother*. 2012; 67: 182–90. doi: [10.1093/jac/dkr409](#) PMID: [21987238](#)
11. Katsuno K, Burrows JN, Duncan K, van Huijsduijnen RH, Kaneko T, Kita K, et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. *Nat Rev Drug Discov*. 2015; 14: 751–8. doi: [10.1038/nrd4683](#) PMID: [26435527](#)
12. Buffet PA, Sulahian A, Garin YJF, Nassar N, Derouin F. Culture microtitration: A sensitive method for quantifying *Leishmania infantum* in tissues of infected mice. *Antimicrob Agents Chemother*. 1995; 39: 2167–2168. PMID: [8540741](#)
13. Hamilton CJ, Saravanamuthu A, Eggleston IM, Fairlamb AH. Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. *Biochem J*. 2003; 369: 529–537. doi: [10.1042/BJ20021298](#) PMID: [12416994](#)
14. Benson TJ, McKie JH, Garforth J, Borges a, Fairlamb a H, Douglas KT. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. *Biochem J*. 1992; 286: 1: 9–11.
15. Holloway GA, Charman WN, Fairlamb AH, et al. Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity. *Antimicrobial Agents and Chemotherapy* 2009; 53(7): 2824–33. doi: [10.1128/AAC.01568-08](#) PMID: [19364854](#)
16. Ribeiro GA, Cunha-Júnior EF, Pinheiro RO, da-Silva SAG, Canto-Cavalheiro MM, da Silva AJM, et al. LQB-118, an orally active pterocarpanquinone, induces selective oxidative stress and apoptosis in *Leishmania amazonensis*. *J Antimicrob Chemother*. 2013; 68: 789–99. doi: [10.1093/jac/dks498](#) PMID: [23288404](#)
17. Lezama-Dávila CM, Isaac-Márquez AP, Barbi J, Cummings HE, Lu B, Satoskar AR. Role of phosphatidylinositol-3-kinase-gamma (PI3Kgamma)-mediated pathway in 17beta-estradiol-induced killing of *L. mexicana* in macrophages from C57BL/6 mice. *Immunol Cell Biol*. 2008; 86(6): 539–43. doi: [10.1038/icb.2008.39](#) PMID: [18542100](#)
18. Zilberstein D, Liveanu V, Gepstein A. Tricyclic drugs reduce proton motive force in *leishmania donovani* promastigotes. *Biochem Pharmacol*. 1990; 39: 935–940. PMID: [1968745](#)
19. Evans AT, Croft SL. Antileishmanial actions of tricyclic neuroleptics appear to lack structural specificity. *Biochem Pharmacol*. 1994; 48: 613–616. PMID: [7915114](#)
20. Costa DL, Rocha RL, Carvalho RM a, Lima-Neto AS, Harhay MO, Costa CHN, et al. Serum cytokines associated with severity and complications of kala-azar. *Pathog Glob Health*. 2013; 107: 78–87. doi: [10.1179/2047773213Y.0000000078](#) PMID: [23683334](#)
21. Ansari NA, Saluja S, Salotra P. Elevated levels of interferon- γ , interleukin-10, and interleukin-6 during active disease in Indian kala azar. *Clin Immunol*. 2006; 119: 339–345. doi: [10.1016/j.clim.2006.01.017](#) PMID: [16540374](#)
22. Costa-Silva TA da, Grecco SS, de Sousa FS, Lago JHG, Martins EGA, Terrazas CA, et al. Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from *Nectandra leucantha*. *J Nat Prod*. 2015; 78: 653–657. doi: [10.1021/np500809a](#) PMID: [25835647](#)
23. Jek H., Persoons A., Schornagel K., Tilders F. H., DeVente J., Berkenbosch F., et al. Alveolar macrophages autoregulate IL-1 and IL-6 production by endogenous nitric oxide. *Am. J. Respir. Cell Mol. Biol*. 1996; 14: 272–278. doi: [10.1165/ajrcmb.14.3.8845178](#) PMID: [8845178](#)

24. Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, Kavuru MS. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. *Am J Respir Cell Mol Biol.* 1997; 17(3): 279–83. doi: [10.1165/ajrcmb.17.3.2998m](https://doi.org/10.1165/ajrcmb.17.3.2998m) PMID: [9308913](https://pubmed.ncbi.nlm.nih.gov/9308913/)
25. Wishah K, Malur A, Raychaudhuri B, Melton AL, Kavuru MS, Thomassen MJ. Nitric oxide blocks inflammatory cytokine secretion triggered by CD23 in monocytes from allergic, asthmatic patients and healthy controls. *Ann Allergy Asthma Immunol.* 2002; 89(1): 78–82. doi: [10.1016/S1081-1206\(10\)61915-1](https://doi.org/10.1016/S1081-1206(10)61915-1) PMID: [12141726](https://pubmed.ncbi.nlm.nih.gov/12141726/)